The
slide to be stained for Epithelial protein Cell Adhesion Molecule
(Ep-CAM) comprised:
1. Appendix, 2. Kidney, 3. Lung adenocarcinoma, 4. Malignant
mesothelioma, epithelial subtype, 5. Clear cell renal carcinoma.
All specimens were fixed in 10 % NBF.
Criteria for assessing an Ep-CAM staining as optimal included:
- A strong, distinct predominantly
membranous staining of the columnar epithelial cells in the
appendix, the renal collecting tubules, and the Bowman capsule
- A strong, distinct predominantly
membranous staining of the lung adenocarcinoma and the clear cell renal carcinoma.
74 laboratories submitted stains. At the assessment 17 achieved
optimal marks (24 %), 21 good (30 %), 17 borderline (24 %) and 15
(21 %) poor marks. Four used an inappropriate Ab (low molecular weight cytokeratin)
and were not assessed.
The following Abs were used:
mAb clone Ber-EP4 (Dako, n=65)
mAb clone MOC31 (Dako, n=4; Euro-diagnostika, n=1)
Optimal staining for Ep-CAM in this assessment was obtained with
both the mAb clone Ber-EP4 (16 out of 65) and the mAb clone
MOC31 (1 out of 5). In optimal stains, no differences in
staining patterns were seen between these two Abs.
With mAb clone Ber-EP4 the
protocols giving an optimal staining result were based on heat
induced epitope retrieval (HIER) either as single pre-treatment or
combined with proteolytic pre-treatment.
Using HIER as single pre-treatment, only Target
Retrieval Solution pH 6,1 (TRS, Dako) could be used as HIER buffer to
obtain an optimal result. Using HIER in TRS the mAb clone Ber-EP4
typically was diluted in the range of 1:25 – 1:200 depending on the
total sensitivity of the protocol employed. In these settings 14
out of 32 (44 %) were assessed as optimal and all 32 were
sufficient (optimal or good). Using a combined pretreatment, HIER in
TRS was followed by Proteinase K. Ber-EP4 was
diluted 1:100. Using these settings 2 out of 2 obtained an optimal
mark.
With mAb clone MOC31 the optimal
result was based on HIER in TRS, the Ab was diluted 1:50.
The most frequent causes of insufficient staining reactions were:
- Too low concentration of the primary Ab
- Inappropriate pretreatment (i.e., HIER in other buffers than TRS;
proteolytic pretreatment)
The prevalent feature of an
insufficient staining was a too weak or false negative staining of
the lung adenocarcinoma and the clear cell
renal carcinoma. In general almost all laboratories were capable of
demonstrating Ep-CAM in the columnar epithelial cells of the appendix,
indicating that appendix/colon cannot be recommended as a reliable
positive control for Ep-CAM. In this assessment normal kidney was an
applicable and valid quality indicator for Ep-CAM, as the ability to
demonstrate Ep-CAM in the Bowman’s capsule and the collecting tubules was characteristic for laboratories obtaining an
optimal mark, and the structures typically were negative in the
insufficient stains. In this assessment the malignant mesothelioma
was positive for Ep-CAM irrespective of the immunohistochemical
method applied and the assessment mark obtained, stressing that
markers for Ep-CAM should be used in a broad Ab panel for the
differential diagnosis of mesothelioma and adenocarcinoma. Actually
several laboratories were not capable to detect Ep-CAM in the lung
adenocarcinoma but demonstrated Ep-CAM in the malignant
mesothelioma!
It should be noticed that the most frequent
cause of insufficient staining in this assessment was the choice of
pre-treatment. HIER in other buffers than TRS or proteolytic pre-treatment
gave an insufficient result in 30 out 32 laboratories. This observation is in concordance with the previous
assessment of Ep-CAM/Ber-EP4 in
run 6 in which only 3 out of 26
obtained an optimal mark using proteolytic pre-treatment, compared to
HIER in Target Retrieval Solution pH 6.1 which resulted in an
optimal mark for 13 out of 18 laboratories. Ep-CAM was also assessed in Run 6 2002, in which 48 laboratories
participated. Out of these 11 laboratories (23 %) had an
insufficient staining. The proportion of insufficient
staining in this run increased to 32 out of 70 laboratories (45 %). The main cause for the
decrease in pass rate is most likely
the large number of new participants, which almost all
used an inappropriate or less efficient pre-treatment. Using an
appropriate pre-treatment as HIER in TRS all of 34 laboratories
obtained a sufficient result.
Conclusion
The mAb clones Ber-EP4 and MOC31 are applicable
markers for Ep-CAM.
HIER in TRS pH 6.1 is highly
recommended for optimal performance with both Abs. Kidney should be
the preferred positive control.
Erratum: In a previous version of this
page, it was indicated that the proximal tubules expressed Ep-CAM.
However, the staining reaction is in the collecting tubules, as also
illustrated in Fig. 4a and described in the Epitopes section (Ep-CAM). |